Participants were randomized to placebo or retatrutide at 1 mg, 4 mg (dose-escalation), 4 mg (no escalation), 8 mg (escalation), 8 mg (no escalation), or 12 mg (escalation) for 48 weeks, following a slow titration protocol
MedicalDaily Evidence Check Study type: Phase 3 randomized controlled trial (ATTAIN program) Participants: Adults with obesity or overweight with at least one weight-related comorbidity Approval date: April 1, 2026 What it found: Average weight loss of approximately 12.4% (about 27 lbs) at highest dose over 72 weeks What it did not prove: That it matches injectable GLP-1 efficacy
The goal is consistency, not forcing large amounts of intake at once
It has an enrolment goal of 405 patients, and it is estimated to last until December 2025
Some researchers also note the concentration in mcg per unit: at 10mg/mL, each unit on a U-100 syringe contains 100mcg (since 10,000mcg per 100 units = 100mcg per unit)
Related Reading Best Time of Day to Take Semaglutide for Weight Loss Does GLP-1 Make You Tired How Long Does It Take for GLP-1 to Work GLP-1 Dosage for Weight Loss GLP-1 Constipation How Long Does It Take for Semaglutide to Suppress Appetite Download our GLP-1 app to Turn Your Weight Loss Journey into Your Favorite Game Starting Ozempic, Wegovy, or Mounjaro